Foot Ulcer ChronicNCT02307448
Effectiveness of Autologous Platelet Rich Plasma in the Treatment of Chronic Non-Healing Wounds
A study testing Platelet Rich Plasma in people with Foot Ulcer Chronic and Skin Ulcer Venous Stasis Chronic, run by ACR Biologics, LLC at 1 site in United States.
Trial summary
This investigation plans to initiate the healing of chronic wounds by providing a concentrated platelet and growth factor therapy directly to the wound site by topical delivery. This therapy will be derived from autologous platelet rich plasma (PRP), an emerging surgical and wound care treatment. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Foot Ulcer Chronic, Skin Ulcer Venous Stasis Chronic, Pressure Ulcer
- What is being tested?
- Platelet Rich Plasma
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 1 siteUnited States
- Study dates
- Aug 2015to Dec 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
6.2 Inclusion Criteria
- Male or female ≥ 18 years of age.
- Wound must be diagnosed as Diabetic Foot Ulcers (DFU), Venous Ulcers (VU), or Pressure Ulcers (PU) with duration greater than 30 days at first visit/patient screening.
- If more than one non-healing wound is present, the largest wound will be selected and must be at least 2cm in size.
- Wound must be classified as Wagner 1 - 3 on the Wagner classification system. Wagner's Classification System Grade 1 Superficial ulcer without subcutaneous tissue involvement Grade 2 Penetration through the subcutaneous tissue (bone, tendon, ligament or joint capsule) Grade 3 Osteitis, abscess or osteomyelitis Grade 4 Gangrene of the forefoot Grade 5 Gangrene of the entire foot
- There must be at least 2 cm between the index wound and other wounds; if all wounds are closer than 2 cm, the patient should not be enrolled (screen failure).
- Wound must be clinically non-infected (A swab or deep tissue culture shall be performed at the discretion of the provider).
- If a female of childbearing potential, the patient must have a negative serum pregnancy test at screening.
- Patient has the capacity to understand and consent to be in the study. Written informed consent must be obtained from either the patient or the patient's legally acceptable representative prior to screening activities.
- Platelet count ≥ 75,000 (according to CBC)
- Hemoglobin (Hgb) level > 9 g/dL (according to CBC)
- Hematocrit (HCT or Ht) level > 27% (according to CBC)
- Ankle-Brachial Index (ABI) Test > 0.7
6.3 Exclusion Criteria
- Male or female <18 years of age
- Patients with known sensitivity to components of the PRP kit (calcium chloride, thrombin, collagen, acid citrate dextrose solution A (ACDA).
- Wound is not a Diabetic Foot Ulcers (DFU), Venous Ulcer (VU), or Pressure Ulcer (PU) at duration of greater than 30 days at first visit/patient screening.
- Wounds smaller than 2cm will be excluded. Exclusion criteria do not include maximum wound size or age.
- Wound that is classified as Wagner 4 - 5 on the Wagner classification system. Wagner's Classification System Grade 1 Superficial ulcer without subcutaneous tissue involvement Grade 2 Penetration through the subcutaneous tissue (bone, tendon, ligament or joint capsule) Grade 3 Osteitis, abscess or osteomyelitis Grade 4 Gangrene of the forefoot Grade 5 Gangrene of the entire foot
- There is less than 2 cm between the index wound and other wounds; if all wounds are closer than 2 cm, the patient should not be enrolled (screen failure).
- Wound is clinically infected. (A swab or deep tissue culture shall be performed at the discretion of the provider).
- Presence of non-treated osteomyelitis.
- If female, patient is pregnant, nursing or plans to become pregnant during the duration of the trial.
- Patients who are cognitively impaired and do not have a healthcare proxy.
- Platelet count < 75,000 (according to CBC)
- Hemoglobin (Hgb) level ≤ 9 g/dL (according to CBC)
- Hematocrit (HCT or Ht) level ≤ 27% (according to CBC)
- Ankle-Brachial Index (ABI) Test ≤ 0.7
- Patient has lymphedema.
- Received electrostimulation, hyperbaric treatments, systemic corticosteroids, growth factors or any cell or tissue derived products for any wounds 30 days prior to entry into the study. (Except for patients receiving inhaled corticosteroid treatments for COPD)
- Received radiation therapy or chemotherapy within previous 3 months.
- Patient has inadequate venous access for repeated blood draw required for PRP preparation.
- Concurrent participation in a clinical trial in which an investigational agent is used.
Trial locations and contacts
1 site in 1 country.
United States1 site
TriHealth Hatton Research Institute | Bethesda North Hospital
Cincinnati, Ohio, 45242
About this study
This investigation plans to initiate the healing of chronic wounds by providing a concentrated platelet and growth factor therapy directly to the wound site by topical delivery. This therapy will be derived from autologous platelet rich plasma (PRP), an emerging surgical and wound care treatment. This investigation aims to demonstrate that patients with chronic, non-healing wounds treated with autologous PRP and standard medical care have a reduction in wound volume and improved healing rate that results in patient-centered clinically significant health outcomes as compared to patients treated with standard medical care only.
Read the detailed description
This is a multicenter randomized controlled trial, with a single-blind parallel design. 1,500 subjects are planned to enroll in the study. Each subject will be assigned to the treatments in random order. The stratified permuted block randomization method will be applied to the patient assignment. In addition to three study populations, i.e., DFU, VU and PU, and study centers, stratification will be based on one overall variable, (1) nutritional status (Low: Prealbumin <12mg/d vs. moderate: Prealbumin >= 12 mg/d) and one variable for each wound type. Diabetic food ulcer will be based on offloading (2a) (Specialty shoes vs. Total contact cast), pressure ulcer will be based on offloading (2b) (mattress vs. cushion), and venous leg ulcer will be based on compression (2c)(Low: <10 mmHG vs. High: >=30mmHG). Randomization will proceed within strata according to a permuted block scheme with a block size, or balancing interval, varying randomly between 2, 4 or 6. The primary endpoint will be evaluated by a blinded physician to avoid the bias.
Total duration of each patient in the study is expected to be 20 weeks.
- Being tested
- Platelet Rich Plasma, Standard of Care
- Medical subject headings
- Pressure Ulcer
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Platelet Rich PlasmaProcedure or surgery
Also called PRP
Patients will receive weekly PRP treatments with standard of care.
Standard of CareProcedure or surgery
Patients will receive weekly standard of care.
| Study group | Role | What they receive |
|---|---|---|
| PRP Group | Active comparator | Patients will receive weekly PRP treatments Receives: Procedure: Platelet Rich Plasma |
| Standard of Care | Placebo comparator | Patients will receive weekly standard of care. Receives: Procedure: Standard of Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Wound Closure
The primary objective of this trial is to evaluate increasing the proportion of wounds with complete closure within 20 weeks of initial treatment
Measured: 20 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Dec 2014 (estimated)
- Study startAug 2015
- Primary completionDec 2022
- Study completionDec 2022
Why it stopped: Lack of patient enrollment and lack of reimbursement
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Foot Ulcer ChronicStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- ACR Biologics, LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Louis Thibodeaux, MD,FACCWS, Principal investigator, TriHealth Hatton Research Institute | Bethesda North Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02307448
- Sponsor's protocol ID
- 10312014
- Status last verified
- Jan 2023
- First submitted
- 2 Dec 2014
- Last updated
- 1 Feb 2023
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of Autologous Platelet Rich Plasma in the Treatment of Chronic Non-Healing Wounds
- ClinicalTrials.gov ID
- NCT02307448
- Acronym / sponsor ID
- 10312014
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Lack of patient enrollment and lack of reimbursement
- Enrolment
- 80 participants (actual)
- Lead sponsor
- ACR Biologics, LLCIndustry (pharma, biotech, devices)
- Study start
- Aug 2015 (actual)
- Primary completion
- Dec 2022 (actual)
- Study completion
- Dec 2022 (actual)
- First posted
- 4 Dec 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This investigation plans to initiate the healing of chronic wounds by providing a concentrated platelet and growth factor therapy directly to the wound site by topical delivery. This therapy will be derived from autologous platelet rich plasma (PRP), an emerging surgical and wound care treatment. This investigation aims to demonstrate that patients with chronic, non-healing wounds treated with autologous PRP and standard medical care have a reduction in wound volume and improved healing rate that results in patient-centered clinically significant health outcomes as compared to patients treated with standard medical care only.
Detailed description
This is a multicenter randomized controlled trial, with a single-blind parallel design. 1,500 subjects are planned to enroll in the study. Each subject will be assigned to the treatments in random order. The stratified permuted block randomization method will be applied to the patient assignment. In addition to three study populations, i.e., DFU, VU and PU, and study centers, stratification will be based on one overall variable, (1) nutritional status (Low: Prealbumin <12mg/d vs. moderate: Prealbumin >= 12 mg/d) and one variable for each wound type. Diabetic food ulcer will be based on offloading (2a) (Specialty shoes vs. Total contact cast), pressure ulcer will be based on offloading (2b) (mattress vs. cushion), and venous leg ulcer will be based on compression (2c)(Low: <10 mmHG vs. High: >=30mmHG). Randomization will proceed within strata according to a permuted block scheme with a block size, or balancing interval, varying randomly between 2, 4 or 6. The primary endpoint will be evaluated by a blinded physician to avoid the bias.
Total duration of each patient in the study is expected to be 20 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| PRP Group | Active comparator | Procedure: Platelet Rich PlasmaPatients will receive weekly PRP treatments |
| Standard of Care | Placebo comparator | Procedure: Standard of CarePatients will receive weekly standard of care. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Platelet Rich PlasmaAlso: PRPPatients will receive weekly PRP treatments with standard of care. | Procedure or surgery | PRP Group |
| Standard of CarePatients will receive weekly standard of care. | Procedure or surgery | Standard of Care |
Primary outcome
Wound Closure
Time frame: 20 weeks
The primary objective of this trial is to evaluate increasing the proportion of wounds with complete closure within 20 weeks of initial treatment
Results and safety
The study was stopped early (reason given: Lack of patient enrollment and lack of reimbursement). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Feb 2023.
Related trials for Foot Ulcer Chronic
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
RecruitingPhase 2
Evaluation of the Safety and Efficacy of Live ASCs in the Treatment of Diabetic Foot Syndrome.
Diabetic Foot Ulcer
RecruitingObservational study
Factors Associated With an Evolution in the Quality of Life of Diabetic Patients With Chronic, Wound-free Charcot Foot
Charcot Joint of Foot, Osteoarthropathy
Not yet recruiting
Subcutaneous Dexpanthenol Administration and Wound Epithelialization
Chronic Wounds, Diabetic Foot Ulcer
RecruitingPhase 3
a Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy of Bioxheal, a Single-layer Placental-derived Biologic in Nonhealing Diabetic Foot Ulcers
Diabetic Foot Ulcer, Amniotic Membrane Placental Allograft
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Louis Thibodeaux, MD,FACCWS principal investigator
TriHealth Hatton Research Institute | Bethesda North Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Platelet Rich Plasma in people with Foot Ulcer Chronic and Skin Ulcer Venous Stasis Chronic, run by ACR Biologics, LLC at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 1 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Lack of patient enrollment and lack of reimbursement). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Wound Closure (time frame: 20 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Feb 2023.